Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate

• Polpharma Biologics and Teva announced a global licensing agreement for a proposed biosimilar to Ocrevus® (ocrelizumab), with Teva obtaining exclusive commercialization rights across major global markets following regulatory approval.
• As the development and manufacturing partner, Chime Biologics successfully advanced the program from cell bank to commercial-scale manufacturing within 10 months, accelerating CMC development and supporting the program's rapid progression toward this important commercial milestone.
• This milestone underscores Chime Biologics' position as a trusted global CDMO for late-phase and commercial biologics, supporting European biopharma companies and enabling successful partnerships with multinational pharmaceutical companies such as Teva.

---

Wuhan, China | July, 2026 — Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, congratulates Polpharma Biologics on its newly announced global licensing agreement with Teva (NYSE and TASE: TEVA), under which Teva has obtained exclusive rights to commercialize Polpharma Biologics' proposed biosimilar to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations, across major global markets following regulatory approval.

As the development and manufacturing partner for this biosimilar program, Chime Biologics is proud to have supported Polpharma Biologics in advancing this important milestone. Leveraging its integrated end-to-end biologics development and manufacturing platform, Chime Biologics successfully progressed the program from cell bank to commercial-scale manufacturing within 10 months, significantly accelerating development timelines to support the program's rapid advancement toward this important commercial milestone.

The licensing agreement marks an important step toward for Chime Biologics to make high-quality, affordable biosimilars available to more patients worldwide. Aligned with Teva’s Pivot to Growth strategy and focus on expanding biosimilars pipeline, the collaboration is expected to accelerate global access to an important treatment option for patients with multiple sclerosis by leveraging the extensive global commercial capabilities of Teva.

This achievement further reinforces Chime Biologics' proven capability in supporting late-phase and commercial biologics programs. It reflects the confidence that leading European biopharma companies such as Polpharma Biologics place in Chime Biologics' development and manufacturing expertise, while also demonstrating that the company's technical excellence, quality systems, and manufacturing execution are recognized by global pharmaceutical leaders such as Teva.

Chime Biologics congratulates Polpharma Biologics and Teva on this significant milestone and is proud to support the continued advancement of this program, contributing to broader global access to high-quality, affordable biologic therapies for patients worldwide.

---

About Polpharma Biologics

Polpharma Biologics International AG is a biopharmaceutical company focused on development and manufacturing of biosimilars for supply to global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch in strong collaboration with our global partners.

Our international team of senior experts has proven experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs and CROs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners ensure access for patients to these medicines worldwide.

Our mission is to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development. www.polpharmabiologics.com

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 700 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.

For more information, please visit www.chimebiologics.com.

About ocrelizumab

Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, which are believed to play a role in the autoimmune activity associated with multiple sclerosis. Ocrevus® (ocrelizumab) is indicated for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. In the U.S., the intravenous formulation is marketed as Ocrevus®, while the subcutaneous formulation is marketed separately as Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq). In the EU, both formulations carry the single brand name Ocrevus®.